

Date: 05 February 2026

To

The Secretary

BSE Limited

Phiroze Jeejeebhoy Towers

Dalal Street

Mumbai - 400 001

Scrip Code: 544293

The Secretary

National Stock Exchange of India Limited

Exchange Plaza, Plot No. C/1. G Block

Bandra -Kurla Complex, Bandra (East)

Mumbai- 400 051

Scrip Symbol : SURAKSHA

Dear Sir / Ma'am,

Reg: Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015

Sub: Press release in respect of unaudited (standalone and consolidated) financial results of the Company for quarter and nine months ended 31 December 2025

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015 please find enclosed herewith, press release in relation to the unaudited (standalone and consolidated) financial results of the Company for quarter and nine months ended 31 December 2025.

Further, details as required to be disclosed as per BSE's Circular No. 20230714-34 dated 14 July 2023, and NSE's Circular No. NSE/CML/2023/57 dated 14 July 2023, are as under:

Date of occurrence of Event/Information: **05 February 2026**

Time of occurrence of Event/Information: **4.25 pm (IST)**

This may please be informed to all the concerned.

For **Suraksha Diagnostic Limited**

Mamta Jain

Company Secretary & Compliance Officer

Encl: As above

Suraksha Diagnostic Limited

CIN: L85110WB2005PLC102265

Reg Office: 12/1, Premises No. 02-0327, DG Block, Action Area 1D, New Town
Kolkata-700 156, West Bengal, India

E-mail: investors@surakshanet.com | **Website:** www.surakshanet.com

Phone: (033) 6605 9750





Top-line and Margin Growth Reflects Higher Test Volumes

Total Income grew by 30.3% year-on-year in Q3 FY26

Q3 FY26 EBITDA grew by 26.1% year-on-year

Kolkata, 05th February 2026: Suraksha Diagnostic Limited, the largest integrated diagnostic chain in East India, announced its unaudited financial results for the quarter and nine months ended 31st December 2025.

Q3 FY26 Financial Performance Snapshot (Y-o-Y)

Total Income	EBITDA	Profit After Tax	EPS
₹ 783.09 million	₹ 237.82 million	₹ 72.41 million	₹ 1.44
 +30.3%	 +26.1%	 +21.0%	 ₹ 0.26

Key Financial Highlights

Particulars	Q3 FY26	Q3 FY25	Y-o-Y	9M FY26	9M FY25	Y-o-Y
Total Income (₹ million)	783.09	601.12	30.3%	2,313.81	1,900.27	21.8%
EBTIDA (₹ million)	237.82	188.55	26.1%	734.04	650.84	12.8%
EBTIDA Margin (%)	30.6%	31.7%		32.1%	34.8%	
PAT (₹ million)	72.41	59.85	21.0%	252.43	238.07	6.0%
PAT Margin (%)	9.3%	10.1%		11.0%	12.7%	

Key Operational Highlights

Particulars	Q3 FY26	Q3 FY25	Y-o-Y	9M FY26	9M FY25	Y-o-Y
Total tests (# million)	2.06	1.57	30.7%	6.18	4.86	27.2%
Total Patients (# million)	0.36	0.29	23.0%	1.07	0.90	19.3%
Tests per patient (#)	5.77	5.43	6.2%	5.78	5.42	6.7%
Average Revenue per test (₹)	378	378	-0.1%	370	385	-3.8%
Average Revenue per patient (₹)	2,181	2,054	6.1%	2,140	2,084	2.7%

Commenting on the results Mrs. Ritu Mittal, Joint Managing Director & CEO said, -

"We continued to generate strong quarterly top-line growth in Q3 FY26 on the back of our robust network expansion.

The EBITDA margin impact was attributable to the launch and development of new centres. Our centres which are > 2 years old continue to operate at a strong 37% EBITDA, indicating the strength of our business model. We are 'Investing for Scale: Short-term Compression for Long -term Dominance'.

In 9M FY26, we added 12 centres which are fully operational, while 6 are under development. With the launch of Suraksha Sutra, our Genomics/Molecular vertical, we have successfully forayed into the high-value genomics segment, securing a strong first-mover advantage in Eastern India.

We are committed to generating value for our shareholders and should be able to drive innovation, operational excellence and sustainable growth."

About Suraksha Diagnostic Limited:

Suraksha Diagnostic Limited is a leading provider of integrated solutions in pathology and radiology testing, as well as medical consultation services, offering a seamless experience to customers through an extensive operational network. The company is the largest integrated diagnostic chain with a presence in the states of West Bengal, Bihar, Assam and Meghalaya.

The company's central reference laboratory is accredited by the College of American Pathologists, while the 4 laboratories hold National Accreditation Board for Testing and Calibration Laboratories (NABL) accreditation, and the 3 advanced diagnostic centres are accredited by the National Accreditation Board for Hospitals & Healthcare Providers (NABH).

Company: Suraksha Diagnostic Limited	Investor Relations: MUFG Intime India Private Limited
Email: investors@surakshanet.com	Name: Mr. Ashish Tendulkar Email: ashish.tendulkar@in.mpms.mufg.com
CIN: L85110WB2005PLC102265	Name: Pooja Swami Email: pooja.swami@in.mpms.mufg.com
Website: https://www.surakshanet.com/	Meeting Request Link – Click Here

Safe Harbor

Any forward-looking statements about expected future events, financial and operating results of the Company are based on certain assumptions which the Company does not guarantee the fulfilment of. Past performance also should not be simply extrapolated into the future. These statements are subject to risks and uncertainties. Actual results might differ substantially or materially from those expressed or implied. Important developments that could affect the Company's operations include a downtrend in the industry, global or domestic or both, significant changes in political and economic environment in India or key markets abroad, tax laws, litigation, labour relations, exchange rate fluctuations, technological changes, investment and business income, cash flow projections, interest, and other costs. The Company does not undertake any obligation to update forward-looking statements to reflect events or circumstances after the date thereof.